Navigation Links
Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer
Date:5/20/2013

we are merging novel pharmacology with local, sustained delivery of drug to the site of disease – an approach that aims to ensure lasting therapeutic effect and systemic safety. We are currently advancing a portfolio of best-in-class drug candidates that have the potential to treat mild, moderate and severe forms of osteoarthritis. Top-line data for FX005, an intra-articular sustained release p38 MAP kinase inhibitor and our lead compound, showed prolonged improvement in joint pain and function throughout the 12-week duration of the Phase 2 study. FX006, an intra-articular sustained release steroid, is currently being evaluated in a Phase 2b dose-ranging study with data expected in the middle of 2013. FX007, an intra-articular sustained release TrkA inhibitor, is being developed to safely address the intractable pain associated with end-stage osteoarthritis.

For more information please visit www.flexiontherapeutics.com.

Editor's Note: Photograph of Frederick Driscoll available on requestMedia ContactsCorporate ContactTony Russo, Ph.D.Lisa Davidson, MBAMatt Middleman, M.D.Vice President, Finance and AdministrationRusso PartnersT: 781-897-9965T: 212-845-425ldavidson@flexiontherapeutics.comT: 212-845-4272 tony.russo@russopartnersllc.com matt.middleman@russopartnersllc.com 
'/>"/>

SOURCE Flexion Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
3. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
6. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
7. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
8. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
9. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
10. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
11. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 Biscayne Pharmaceuticals, Inc ., ... its growth hormone-releasing hormone (GHRH) technology will be discussed in ... Annual Meeting. The data show that the family of ... blockers, is present on many primary breast cancer cells ... GHRH antagonists could have broad anti-cancer potential in breast ...
(Date:5/28/2015)... Whitehouse Laboratories is excited to announce ... partnership with PTI Inspection Systems. Whitehouse Labs and PTI ... custom-tailored method development and validation programs using the ... agreement includes a more formal program that facilitates cross ... This enables a more effective team approach, especially as ...
(Date:5/28/2015)... Clinerion, an eClinical technology ... the Alliance for Clinical Research Excellence and ... operating in the public interest and dedicated ... quality, safety, integrity and operational effectiveness in ... pleased to announce their partnership for accelerating ...
(Date:5/27/2015)... The Academy of Model Aeronautics Foundation would like to ... Day. The third annual celebration will be August 15, 2015. ... aviation hobby nation-wide and to introduce model flying to the ... clubs to celebrate the hobby and share it with the ... also be a local event at the AMA headquarters in ...
Breaking Biology Technology:Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 3Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 2Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 3Academy of Model Aeronautics Foundation to host National Model Aviation Day Motorcycle Rally and Family Fest in Muncie, IN 2Academy of Model Aeronautics Foundation to host National Model Aviation Day Motorcycle Rally and Family Fest in Muncie, IN 3
... to Move ... Science Forward, MUNICH, Germany, March 31 ... serving science, today,launched a number of innovative new products at Analytica 2008, ... - 4. The company,s new technologies are focused on enabling,customers to take ...
... Inc., a,biopharmaceutical company developing and commercializing therapies for,vascular disorders, ... full year 2007 financial results., 2007 Year ... clinical study -- Received FDA approval to ... Kinlytic(TM) -- Signed strategic licensing ...
... Calif., March 31 Varian, Inc.,(NasdaqGS: VARI) ... UltiMetal(TM),column for high temperature gas chromatography (GC), ... conditions. These highly durable columns,allow chemists to ... up,to 450 degrees Celsius. Based on a ...
Cached Biology Technology:Thermo Fisher Scientific Unveils New Laboratory Technologies at Analytica 2008 2Thermo Fisher Scientific Unveils New Laboratory Technologies at Analytica 2008 3Thermo Fisher Scientific Unveils New Laboratory Technologies at Analytica 2008 4Thermo Fisher Scientific Unveils New Laboratory Technologies at Analytica 2008 5Thermo Fisher Scientific Unveils New Laboratory Technologies at Analytica 2008 6Thermo Fisher Scientific Unveils New Laboratory Technologies at Analytica 2008 7ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 2ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 3ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 4ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 5ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 6ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 7ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 8ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 9ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007 10New Capillary Column From Varian, Inc. Offers Durability and Performance for High Temperature GC and GC/MS 2
(Date:5/26/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/p2kc6z/saudi_arabia ... "Saudi Arabia Biometric Systems Market Forecast and Opportunities, ... http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems market in ... grow at over 22% CAGR through 2020 ... surging demand for better biometric technologies in the ...
(Date:5/22/2015)... DALLAS , May 22, 2015 ... Recognition Market by Solution (2D, 3D, Thermal, Emotion, Forensic), by ... End User (Government and Utilities, Consumer and Home) - ... Market to grow from $2.77 Billion in 2015 to ... Browse 79 market data Tables and ...
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
... a novel gene therapy aimed at selectively turning off ... Parkinson's disease. , The gene therapy, described in the ... designed by Martha Bohn and her laboratory group at ... is Medical Research Council Professor and director of the ...
... mate is a big decision. And, at least for mice, it's ... In a series of experiments designed help scientists understand the brain ... mice to odors of either a male mouse alone or a ... of males linked to other females. , "Our data suggest that ...
... biological weapons are created equal. They are separated into ... the scariest: They are easy to spread, kill effectively ... system. One of these worrisome organisms is anthrax, which ... But work in Vince Fischetti's laboratory at Rockefeller University ...
Cached Biology News:Gene therapy 'turns off' mutation linked to Parkinson's disease 2When mice choose mates, experience counts 2Newly discovered protein kills anthrax bacteria by exploding their cell walls 2
... Feature Extraction Software reads ... files to prepare microarray data ... , * one 2-year ... for NFP/Academic accounts , * ...
... and SYBR Safe DNA Gel Stain combo offers these ... buying these same products separately ... bromide Eliminates risks to ... and RNA fragments from 100 bp to >30 kb. ...
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
... uses continuous chemical suppression and thermally stabilized ... accurate determinations of common anions and cations ... quick to equilibrate, and fully automated with ... you achieve maximum sample throughput at minimum ...
Biology Products: